Zsofia Stadler

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5738734/publications.pdf

Version: 2024-02-01

35 papers	3,037 citations	430874 18 h-index	361022 35 g-index
36 all docs	36 docs citations	36 times ranked	5615 citing authors

#	Article	IF	Citations
1	Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores. Journal of the National Cancer Institute, 2022, 114, 109-122.	6.3	19
2	Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes. JCO Oncology Practice, 2022, 18, 201-209.	2.9	34
3	Factors Influencing Patient Preferences for Telehealth Cancer Genetic Counseling During the COVID-19 Pandemic. JCO Oncology Practice, 2022, 18, e462-e471.	2.9	8
4	Simplified Graded Infusion Strategy for Mitigation of Oxaliplatin Hypersensitivity. Clinical Colorectal Cancer, 2022, , .	2.3	2
5	ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications. Journal of the National Cancer Institute, 2022, 114, 761-770.	6.3	3
6	Intratumoral T-cell repertoires in DNA mismatch repair-proficient and -deficient colon tumors containing high or low numbers of tumor-infiltrating lymphocytes. OncoImmunology, 2022, 11, 2054757.	4.6	3
7	PD-1 Blockade in Mismatch Repairâ€“Deficient, Locally Advanced Rectal Cancer. New England Journal of Medicine, 2022, 386, 2363-2376.	27.0	588
8	Primary Clonal Loss of Mismatch Repair Protein on Immunohistochemistry: A Pattern of Abnormality That Warrants Genetic Workup. JCO Precision Oncology, 2022, , .	3.0	1
9	Prevalence and Characterization of Biallelic and Monoallelic NTHL1 and MSH3 Variant Carriers From a Pan-Cancer Patient Population. JCO Precision Oncology, 2021, 5, 455-465.	3.0	10
10	Clinical Calculator Based on Molecular and Clinicopathologic Characteristics Predicts Recurrence Following Resection of Stage I-III Colon Cancer. Journal of Clinical Oncology, 2021, 39, 911-919.	1.6	34
11	Tumor-Infiltrating Lymphocytes, Tumor Mutational Burden, and Genetic Alterations in Microsatellite Unstable, Microsatellite Stable, or Mutant POLE/POLD1 Colon Cancer. JCO Precision Oncology, 2021, 5, 817-826.	3.0	18
12	A Coordinated Clinical Center for Young Onset Colorectal Cancer. Oncologist, 2021, 26, 625-629.	3.7	8
13	The predictive ability of the 313 variantâ€“based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737.	2.4	16
14	Paired Tumor-Normal Sequencing Provides Insights into TP53-Related Cancer Spectrum in Li-Fraumeni Patients. Journal of the National Cancer Institute, 2021, , .	6.3	6
15	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. Journal of Clinical Oncology, 2021, 39, 2698-2709.	1.6	83
16	Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery. JAMA Network Open, 2021, 4, e2133457.	5.9	16
17	Quantitative assessment of tumor-infiltrating lymphocytes in mismatch repair proficient colon cancer. OncoImmunology, 2020, 9, 1841948.	4.6	3
18	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nature Genetics, 2020, 52, 1219-1226.	21.4	367

#	Article	IF	Citations
19	Induction Chemotherapy Reduces Patient-reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiotherapy for Rectal Cancer. Clinical Colorectal Cancer, 2019, 18, 167-174.	2.3	3
20	Toward automation of germline variant curation in clinical cancer genetics. Genetics in Medicine, 2019, 21, 2116-2125.	2.4	27
21	Understanding Inherited Risk in Unselected Newly Diagnosed Patients With Endometrial Cancer. JCO Precision Oncology, 2019, 3, 1-15.	3.0	7
22	Germline SDHA mutations in children and adults with cancer. Journal of Physical Education and Sports Management, 2018, 4, a002584.	1.2	33
23	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
24	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	2.5	18
25	Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data. JCO Precision Oncology, 2017, 2017, 1-17.	3.0	209
26	Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nature Reviews Clinical Oncology, 2016, 13, 581-588.	27.6	258
27	Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. JAMA Oncology, 2016, 2, 104.	7.1	270
28	Variation in the Attitudes of Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast Cancer. Oncologist, 2015, 20, 992-1000.	3.7	8
29	Germline EGFR T790M Mutation Found in Multiple Members of a Familial Cohort. Journal of Thoracic Oncology, 2014, 9, 554-558.	1.1	63
30	Secondary mutation in a coding mononucleotide tract in MSH6 causes loss of immunoexpression of MSH6 in colorectal carcinomas with MLH1/PMS2 deficiency. Modern Pathology, 2013, 26, 131-138.	5.5	82
31	Susceptibility Loci Associated with Specific and Shared Subtypes of Lymphoid Malignancies. PLoS Genetics, 2013, 9, e1003220.	3.5	44
32	Risk of metachronous breast cancer after BRCA mutationâ€“associated ovarian cancer. Cancer, 2013, 119, 1344-1348.	4.1	58
33	Assessment of SLX4 Mutations in Hereditary Breast Cancers. PLoS ONE, 2013, 8, e66961.	2.5	37
34	Immunohistochemical Staining for DNA Mismatch Repair Proteins in Intestinal Tract Carcinoma. American Journal of Surgical Pathology, 2011, 35, 447-454.	3.7	82
35	Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer. Clinical Cancer Research, 2010, 16, 2115-2121.	7.0	263